Related Experiment Videos
High-titer glucagon antibodies in a hypoglycemic child on glucagon therapy
Journal of Pediatric Gastroenterology and Nutrition
|January 1, 1982
Insights
High levels of antiglucagon antibodies were found in a young patient with nesidioblastosis. Glucagon treatment remained essential for blood glucose stability despite surgery.
Area of Science:
- Endocrinology
- Immunology
- Pediatrics
Background:
- Nesidioblastosis is a rare condition characterized by an overgrowth of pancreatic islet cells.
- Glucagon is a hormone crucial for maintaining blood glucose homeostasis.
- Treatment with exogenous glucagon may be necessary in specific pediatric endocrine disorders.
Observation:
- A 14-month-old patient with nesidioblastosis developed high-titer antiglucagon antibodies (1:30,000) after 5 months of intramuscular long-acting glucagon therapy.
- The patient required continuous glucagon treatment to achieve blood glucose equilibrium, even after a subtotal pancreatectomy.
- Antiglucagon antibody titers remained stable at 18 months of age.
Findings:
- The development of high-titer antiglucagon antibodies in response to therapeutic glucagon administration.
- Persistent dependence on glucagon treatment for glycemic control, suggesting antibody interference or disease progression.
- The stability of the antibody titer over a 4-month period.
Implications:
- This case highlights a potential immunogenic response to therapeutic glucagon in pediatric patients.
- Understanding antibody formation is critical for managing endocrine disorders requiring hormone replacement.
- Further research is needed to explore the long-term consequences and management strategies for antibody-mediated resistance to glucagon therapy.
Abstract:
High-titer (1:30,000) antiglucagon antibodies were detected in a 14-month-old patient with nesidioblastosis who had been treated by intramuscular long-acting glucagon since age 5 months. In this patient no correct equilibrium of blood glucose level could be obtained without maintaining glucagon treatment, even after subtotal pancreatectomy. Antiglucagon antibodies titer remained stable at age 18 months.